

DAFTAR PUSTAKA

1. Tomlinson-Hansen S, Khan M, Cessaro S. Breast Ductal Carcinoma In Situ. StatPearls [Internet]. 2023. p. 1–12.
2. International Agency of Research on Cancer GLOBOCAN 2020. Estimated age-standardized incidence and mortality rates (Word) in 2020, worldwide both sexes, all age (Diakses 12 Januari 2022) Dari <http://gco.iarc.fr/today/home>
3. Grimm LJ, Rahbar H, Abdelmalak M, Hall AH, Ryser MD. Ductal Carcinoma in Situ: State-of-the-Art Review. Radiology. 2022 Feb 1;302(2):246–55.
4. Haji F, Baker JL, DiNome ML. Updates on treating ductal carcinoma in situ: what's to know in 2021. Curr Opin Obstet Gynecol. 2022 Feb 1;34(1):46–51.
5. American Cancer Society. Cancer Facts & Figures [Internet] 2024. Available from <http://www.cancer.org>
6. Gursoy M, Oktay A, Aslan O, Zekioglu O. High-Grade Ductal Carcinoma in Situ of the Breast with Regressive Changes: Radiological and Clinicopathological Findings. Eur J Breast Health. 2023 Apr 1;19(2):140–7.
7. Sanati S. Morphologic and Molecular Features of Breast Ductal Carcinoma in Situ. American Journal of Pathology. 2019 May 1;189(5):946–55.
8. Hophan SL, Odnokoz O, Liu H, Luo Y, Khan S, Gradishar W, et al. Ductal Carcinoma In Situ of Breast: From Molecular Etiology to Therapeutic Management. Endocrinology. 2022 Apr 1;163(4):1–9.
9. Kalwaniya DS, Gairola M, Gupta S, Pawan G. Ductal Carcinoma in Situ: A Detailed Review of Current Practices. Cureus. 2023 Apr 21;15(4):1–9.
10. Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, et al. Breast Cancer, Version 3.2022. Journal of the National Comprehensive Cancer Network. 2022 Jun 1;20(6):691–722.
11. Li Y, Giovannini S, Wang T, Fang J, Li P, Shao C, et al. p63: a crucial player in epithelial stemness regulation. Oncogene. 2023 Nov 10;42(46):3371–84.
12. Setiawan I. Peran Pemeriksaan Imunohistokimia dalam Diagnosis dan Prognosis Kanker Payudara. CDK-319. 2023;50(8):443–6.
13. Aden D, Afroze N, Zaheer S, Ehsan A, Hassan Z, Aziz M. The role of p63 myoepithelial cell marker in problematic breast lesion. Hamdan Medical Journal. 2023;16(3):278–85.
14. Steurer S, Riemann C, Büscheck F, Luebke AM, Kluth M, Hube-Magg C, et al. p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors. Biomark Res. 2021 Dec 1;9(1):1–14.

15. Bonev V V. Ductal carcinoma in situ: current and future management for the surgeon and non-surgeon: a narrative review. *AME Surgical Journal*. 2021 Dec;1–11.
16. Bistoni G, Farhadi J. Anatomy and Physiology of the Breast. In: *Plastic and Reconstructive Surgery: Approaches and Techniques*. wiley; 2015. p. 477–85.
17. American Cancer Society. Special Section: Breast Carcinoma In Situ. 2015. Available from <http://www.cancer.org>
18. Łukasiewicz S, Czezelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—An updated review. *Cancers (Basel)*. 2021 Sep 1;13(4287):1–30.
19. Parikh U, Chhor CM, Mercado CL. Ductal carcinoma in situ: The whole truth. *American Journal of Roentgenology*. 2018 Feb 1;210(2):246–55.
20. Luffarelli P, Manna E, Fortunato L. Epidemiology and Risk Factors. In: Mariotti C, editor. *Ductal Carcinoma In Situ of The Breast*. Switzerland: Springer International Publishing AG; 2018. p. 23–37.
21. Coleman WB. Breast Ductal Carcinoma in Situ: Precursor to Invasive Breast Cancer. *American Journal of Pathology*. 2019 May 1;189(5):942–5.
22. Hophan SL, Odnokoz O, Liu H, Luo Y, Khan S, Gradishar W, et al. Ductal Carcinoma In Situ of Breast: From Molecular Etiology to Therapeutic Management. *Endocrinology*. 2022 Apr 1;163(4):1–9.
23. van Seijen M, Lips EH, Thompson AM, Nik-Zainal S, Futreal A, Hwang ES, et al. Ductal carcinoma in situ: to treat or not to treat, that is the question. *Br J Cancer*. 2019 Aug 13;121(4):285–92.
24. Salvatorelli L, Puzzo L, Vecchio GM, Caltabiano R, Virzi V, Magro G. Ductal carcinoma in situ of the breast: An update with emphasis on radiological and morphological features as predictive prognostic factors. *Cancers (Basel)*. 2020 Mar 1;12(609):1–11.
25. Sanati S. Morphologic and Molecular Features of Breast Ductal Carcinoma in Situ. *American Journal of Pathology*. 2019 May 1;189(5):946–55.
26. Bane A. Ductal Carcinoma In Situ : What the Pathologist Needs to Know and Why . *Int J Breast Cancer*. 2013;1–7.
27. College of American Pathologists. Protocol for the Examination of Specimens From Patients With Invasive Carcinoma of the Breast [Internet]. 2018. Available from: www.cap.org/cancerprotocols.

28. Gorringer KL, Fox SB. Ductal Carcinoma In Situ Biology, Biomarkers, and Diagnosis. *Front Oncol*. 2017 Oct 23;7(248):1–14.
29. Garganese G, Fragomeni SM, Bove S, Evangelista MT, Paris I, Di Giorgio D, et al. Current controversies in the treatment of ductal carcinoma in situ of the breast. *Transl Cancer Res*. 2018 Apr 1;7(3):S307–18.
30. Hanna WM, Parra-Herran C, Lu FI, Slodkowska E, Rakovitch E, Nofech-Mozes S. Ductal carcinoma in situ of the breast: an update for the pathologist in the era of individualized risk assessment and tailored therapies. *Modern Pathology*. 2019 Jul 1;32:896–915.
31. Fisher ML, Balint S, Mills AA. p63-related signaling at a glance. *J Cell Sci*. 2021 Sep 1;133(17):1–9.
32. Alkhayyat R, Abbas A, Quinn CM, Rakha EA. Tumour 63 protein (p63) in breast pathology: biology, immunohistochemistry, diagnostic applications, and pitfalls. *Histopathology*. 2023;1–19.
33. Yoh K, Prywes R. Pathway regulation of p63, a director of epithelial cell fate. *Front Endocrinol (Lausanne)*. 2015;6(51):1–9.
34. Russell TD, Jindal S, Agunbiade S, Gao D, Troxell M, Borges VF, et al. Myoepithelial cell differentiation markers in ductal carcinoma in situ progression. *American Journal of Pathology*. 2015 Nov 1;185(11):3076–89.
35. Teresa L, Tanwir J, Mukawi, Achmad Sjawqie, Murnisari Darjan, Lasma Silitonga. Penurunan imunoekspresi p63 pada mioepitel Ductal Carcinoma In Situ (DCIS) Payudara sebagai prediktor Infiltrasi Tumor. 2009:1-5.
36. Durre A, Nishat, Sufian Z, Aaliya E, Zainab H, Maher. The role of p63 Myoepitel cell marker in problematic breast lesion. 2023;16:278-85.
37. Stevens A, Lowe J, Scott I, editor (penyunting). *Core Pathology*. Edisi ke-3. United Kingdom: Elsevier; 2009.